Palliative radiotherapy in cancers of female genital tract: Outcomes and prognostic factors
AuthorsHarsha Kombathula, Sri
Joshi, P. V.
Barraclough, Lisa H
Hoskin, Peter J
AffiliationThe Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom
MetadataShow full item record
AbstractBackground and purpose: Metastatic and incurable cancers of the gynaecological tract (FGTC) represent a major global health burden. Systemic treatment has modest efficacy and radiotherapy is often used for local symptoms. This study combines experience from two large UK centres in palliative radiotherapy for gynaecological cancers. Materials and methods: Pooled data from two major centres was analysed. Advanced FGTC patients who received at least one fraction of palliative radiotherapy to the pelvis between 2013 and 2018 were included. Data collected included demographic and tumour details, radiotherapy dose fractionation and details of previous and subsequent treatment. Response was defined in terms of toxicity, symptomatic response and survival. Comorbidities were recorded using a modified ACE 27 score which is adjusted for the presence of uncontrolled FGTC in all the patients. Results: A total of 184 patients were included for treatment response and toxicity; survival data was available for 165 patients. Subjective response in pre-radiotherapy symptoms was documented in 80.4%. Grade 3 or worse gastrointestinal, urinary and other (vomiting, fatigue, pain) toxicity incidence was 2.2%, 3.8%, and 2.7% respectively. No statistically significant correlation between the prescribed EQD210 and symptom control or toxicity was seen. 1 year overall survival was 25.1% (median 5.9 months). Absent distant metastases, completion of the intended course of radiotherapy, response to radiotherapy, and receipt of further lines of treatment were independent prognostic factors. Conclusion: Palliative radiotherapy is effective for symptoms of advanced FGTC with low toxicity. The absence of a dose response argues for short low dose palliative radiotherapy schedules to be used.
CitationHarsha Kombathula S, Cree A, Joshi PV, Akturk N, Barraclough LH, Haslett K, et al. Palliative radiotherapy in cancers of female genital tract: Outcomes and prognostic factors. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022 Aug 11. PubMed PMID: 35964765. Epub 2022/08/15. eng.
JournalRadiotherapy and Oncology
- A hypofractionated radiotherapy regimen (0-7-21) for advanced gynaecological cancer patients.
- Authors: Yan J, Milosevic M, Fyles A, Manchul L, Kelly V, Levin W
- Issue date: 2011 Sep
- Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review.
- Authors: Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG
- Issue date: 2014 Feb
- Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01).
- Authors: Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R, TROG 03.01/CCTG ES.2 group
- Issue date: 2018 Feb
- Short-course accelerated radiotherapy in palliative treatment of advanced pelvic malignancies: a phase I study.
- Authors: Caravatta L, Padula GD, Macchia G, Ferrandina G, Bonomo P, Deodato F, Massaccesi M, Mignogna S, Tambaro R, Rossi M, Flocco M, Scapati A, Scambia G, Pacelli F, Valentini V, Cellini N, Morganti AG
- Issue date: 2012 Aug 1
- Radiotherapy for palliation of symptoms in incurable cancer.
- Authors: Hoegler D
- Issue date: 1997 May-Jun